Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocular Therapeut (NQ: OCUL )

6.170 -0.100 (-1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,186,468
Open 6.250
Bid (Size) 6.000 (10)
Ask (Size) 6.250 (20)
Prev. Close 6.270
Today's Range 6.050 - 6.260
52wk Range 1.995 - 11.31
Shares Outstanding 154,888,915
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OCUL Stock Earnings: Ocular Therapeutix Misses EPS, Misses Revenue for Q1 2024
OCUL stock results show that Ocular Therapeutix missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga

Performance

YTD
+28.27%
+28.27%
1 Month
-18.60%
-18.60%
3 Month
-18.60%
-18.60%
6 Month
+170.61%
+170.61%
1 Year
-3.14%
-3.14%

More News

Read More
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
2 Small-Cap Growth Stocks With Room To Run
Via The Motley Fool
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
Via Benzinga
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
Via Benzinga
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Decoding 6 Analyst Evaluations For Ocular Therapeutix
Via Benzinga
Ocular Therapeutix: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Ocular Therapeutix
Via Benzinga
Million-Dollar Bets: 3 Under-$15 Stocks With Massive Potential
Via InvestorPlace
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For March 11, 2024
Via Benzinga
$7M Bet On Ocular Therapeutix? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Piper Sandler Maintains Overweight Rating for Ocular Therapeutix: Here's What You Need To Know
Via Benzinga
3 Stocks to Buy That Are Up 100% or More in 2024
Via InvestorPlace
Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.